|
Volumn 338, Issue 23, 1998, Pages 1696-1698
|
Conflict of interest in the debate over calcium-channel antagonists [1] (multiple letters)
|
Author keywords
[No Author keywords available]
|
Indexed keywords
CALCIUM CHANNEL BLOCKING AGENT;
DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;
LONG ACTING DRUG;
NIFEDIPINE;
VERAPAMIL;
CLINICAL TRIAL;
CONFLICT;
DRUG INDUSTRY;
DRUG RESEARCH;
DRUG SAFETY;
EVIDENCE BASED MEDICINE;
FINANCIAL MANAGEMENT;
HUMAN;
HYPERTENSION;
LETTER;
MEDICAL LITERATURE;
PRIORITY JOURNAL;
PUBLICATION;
SIDE EFFECT;
CONFLICT OF INTEREST;
ECONOMICS;
NOTE;
PHYSICIAN;
WRITING;
PERSONNEL;
CLASSIFICATION;
AUTHORSHIP;
CALCIUM CHANNEL BLOCKERS;
CONFLICT OF INTEREST;
DRUG INDUSTRY;
HUMANS;
PHYSICIANS;
RESEARCH SUPPORT;
RESEARCH PERSONNEL;
|
EID: 0032482331
PISSN: 00284793
EISSN: None
Source Type: Journal
DOI: 10.1056/NEJM199806043382313 Document Type: Letter |
Times cited : (8)
|
References (0)
|